Company profile KURA
After 39 days of this quarter the interest is at 161.0. Based on that we can calculate that during remaining 52 days it will total up to 376.0. Kura Oncology expected interest is significantly higher compared to previous quarter (+48.0%) and same quarter last year (+102.2%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 71 | 107 50.7% QoQ | 85 -20.6% QoQ | 134 57.6% QoQ |
| 2020 | 114 60.6% YoY -14.9% QoQ | 334 212.1% YoY 193.0% QoQ | 292 243.5% YoY -12.6% QoQ | 218 62.7% YoY -25.3% QoQ |
| 2021 | 237 107.9% YoY 8.7% QoQ | 168 -49.7% YoY -29.1% QoQ | 105 -64.0% YoY -37.5% QoQ | 90 -58.7% YoY -14.3% QoQ |
| 2022 | 167 -29.5% YoY 85.6% QoQ | 212 26.2% YoY 26.9% QoQ | 149 41.9% YoY -29.7% QoQ | 227 152.2% YoY 52.3% QoQ |
| 2023 | 186 11.4% YoY -18.1% QoQ | 133 -37.3% YoY -28.5% QoQ | 211 41.6% YoY 58.6% QoQ | 254 11.9% YoY 20.4% QoQ |
| 2024 | 161 -13.4% YoY -36.6% QoQ | - | - | - |
The average 5 years interest of Kura Oncology was 14.0 per week. The last year interest of Kura Oncology compared to the last 5 years has changed by 20.5%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 93.69%.
There is not enough data for Kura Oncology company profile to provide analysis
There is not enough data for Kura Oncology company profile to provide correlation calculation
There is not enough data for Kura Oncology company profile to provide analysis
There is not enough data for Kura Oncology biopharmaceutical to provide analysis
There is not enough data for Kura Oncology biopharmaceutical to provide correlation calculation
There is not enough data for Kura Oncology biopharmaceutical to provide analysis
There is not enough data for Kura Oncology medicines to provide analysis
There is not enough data for Kura Oncology medicines to provide correlation calculation
There is not enough data for Kura Oncology medicines to provide analysis
Google Trends for ziftomenib
Q4 +76.3% YoY, +110.1% QoQ | Q1 inf% YoY, +28.8% QoQ | Correlation: nan
After 39 days of this quarter the interest is at 82.0. Based on that we can calculate that during remaining 52 days it will total up to 191.0. ziftomenib expected interest is significantly higher compared to previous quarter (+92.9%) and same quarter last year (+124.7%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 18 | 76 322.2% QoQ | 35 -53.9% QoQ | 48 37.1% QoQ |
| 2020 | 14 -22.2% YoY -70.8% QoQ | 55 -27.6% YoY 292.9% QoQ | 0 -100.0% YoY -100.0% QoQ | 123 156.2% YoY inf% QoQ |
| 2021 | 56 300.0% YoY -54.5% QoQ | 62 12.7% YoY 10.7% QoQ | 129 inf% YoY 108.1% QoQ | 99 -19.5% YoY -23.3% QoQ |
| 2022 | 119 112.5% YoY 20.2% QoQ | 35 -43.5% YoY -70.6% QoQ | 88 -31.8% YoY 151.4% QoQ | 75 -24.2% YoY -14.8% QoQ |
| 2023 | 85 -28.6% YoY 13.3% QoQ | 106 202.9% YoY 24.7% QoQ | 87 -1.1% YoY -17.9% QoQ | 99 32.0% YoY 13.8% QoQ |
| 2024 | 82 -3.5% YoY -17.2% QoQ | - | - | - |
The average 5 years interest of ziftomenib was 5.71 per week. The last year interest of ziftomenib compared to the last 5 years has changed by 25.92%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 95.91%.
There is not enough data for menin-lysine K-specific Methyltransferase 2A inhibitor to provide analysis
There is not enough data for menin-lysine K-specific Methyltransferase 2A inhibitor to provide correlation calculation
There is not enough data for menin-lysine K-specific Methyltransferase 2A inhibitor to provide analysis
After 39 days of this quarter the interest is at 198.0. Based on that we can calculate that during remaining 52 days it will total up to 462.0. acute leukemias expected interest is significantly higher compared to same quarter last year (+437.2%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 225 | 140 -37.8% QoQ | 68 -51.4% QoQ | 47 -30.9% QoQ |
| 2020 | 99 -56.0% YoY 110.6% QoQ | 64 -54.3% YoY -35.4% QoQ | 31 -54.4% YoY -51.6% QoQ | 133 183.0% YoY 329.0% QoQ |
| 2021 | 154 55.6% YoY 15.8% QoQ | 90 40.6% YoY -41.6% QoQ | 73 135.5% YoY -18.9% QoQ | 88 -33.8% YoY 20.5% QoQ |
| 2022 | 249 61.7% YoY 183.0% QoQ | 321 256.7% YoY 28.9% QoQ | 24 -67.1% YoY -92.5% QoQ | 170 93.2% YoY 608.3% QoQ |
| 2023 | 86 -65.5% YoY -49.4% QoQ | 251 -21.8% YoY 191.9% QoQ | 206 758.3% YoY -17.9% QoQ | 333 95.9% YoY 61.7% QoQ |
| 2024 | 198 130.2% YoY -40.5% QoQ | - | - | - |
The average 5 years interest of acute leukemias was 11.69 per week. The last year interest of acute leukemias compared to the last 5 years has changed by 65.95%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 99.38%.
After 39 days of this quarter the interest is at 48.0. Based on that we can calculate that during remaining 52 days it will total up to 112.0. acute myeloid leukemia expected interest is significantly lower compared to same quarter last year (-53.5%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 68 | 114 67.6% QoQ | 113 -0.9% QoQ | 100 -11.5% QoQ |
| 2020 | 107 57.4% YoY 7.0% QoQ | 106 -7.0% YoY -0.9% QoQ | 119 5.3% YoY 12.3% QoQ | 114 14.0% YoY -4.2% QoQ |
| 2021 | 112 4.7% YoY -1.8% QoQ | 118 11.3% YoY 5.4% QoQ | 113 -5.0% YoY -4.2% QoQ | 111 -2.6% YoY -1.8% QoQ |
| 2022 | 139 24.1% YoY 25.2% QoQ | 126 6.8% YoY -9.4% QoQ | 129 14.2% YoY 2.4% QoQ | 111 0.0% YoY -14.0% QoQ |
| 2023 | 241 73.4% YoY 117.1% QoQ | 139 10.3% YoY -42.3% QoQ | 127 -1.6% YoY -8.6% QoQ | 120 8.1% YoY -5.5% QoQ |
| 2024 | 48 -80.1% YoY -60.0% QoQ | - | - | - |
The average 5 years interest of acute myeloid leukemia was 9.48 per week. The last year interest of acute myeloid leukemia compared to the last 5 years has changed by 26.79%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 43.1%.
After 39 days of this quarter the interest is at 140.0. Based on that we can calculate that during remaining 52 days it will total up to 327.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 221 | 336 52.0% QoQ | 321 -4.5% QoQ | 369 15.0% QoQ |
| 2020 | 369 67.0% YoY 0.0% QoQ | 348 3.6% YoY -5.7% QoQ | 307 -4.4% YoY -11.8% QoQ | 331 -10.3% YoY 7.8% QoQ |
| 2021 | 311 -15.7% YoY -6.0% QoQ | 281 -19.3% YoY -9.6% QoQ | 302 -1.6% YoY 7.5% QoQ | 294 -11.2% YoY -2.6% QoQ |
| 2022 | 328 5.5% YoY 11.6% QoQ | 386 37.4% YoY 17.7% QoQ | 348 15.2% YoY -9.8% QoQ | 425 44.6% YoY 22.1% QoQ |
| 2023 | 375 14.3% YoY -11.8% QoQ | 330 -14.5% YoY -12.0% QoQ | 358 2.9% YoY 8.5% QoQ | 344 -19.1% YoY -3.9% QoQ |
| 2024 | 140 -62.7% YoY -59.3% QoQ | - | - | - |
The average 5 years interest of acute lymphoblastic leukemia was 26.15 per week. The last year interest of acute lymphoblastic leukemia compared to the last 5 years has changed by 1.64%. The interest for acute lymphoblastic leukemia is seasonal. The last year interest is comparable to 5 years ago. It has changed only by -1.19%.
After 39 days of this quarter the interest is at 135.0. Based on that we can calculate that during remaining 52 days it will total up to 315.0. tipifarnib expected interest is significantly higher compared to previous quarter (+221.4%) and same quarter last year (+238.7%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 111 | 52 -53.2% QoQ | 78 50.0% QoQ | 38 -51.3% QoQ |
| 2020 | 76 -31.5% YoY 100.0% QoQ | 45 -13.5% YoY -40.8% QoQ | 145 85.9% YoY 222.2% QoQ | 134 252.6% YoY -7.6% QoQ |
| 2021 | 78 2.6% YoY -41.8% QoQ | 86 91.1% YoY 10.3% QoQ | 128 -11.7% YoY 48.8% QoQ | 189 41.0% YoY 47.7% QoQ |
| 2022 | 102 30.8% YoY -46.0% QoQ | 98 14.0% YoY -3.9% QoQ | 135 5.5% YoY 37.8% QoQ | 132 -30.2% YoY -2.2% QoQ |
| 2023 | 93 -8.8% YoY -29.5% QoQ | 176 79.6% YoY 89.2% QoQ | 16 -88.1% YoY -90.9% QoQ | 98 -25.8% YoY 512.5% QoQ |
| 2024 | 135 45.2% YoY 37.8% QoQ | - | - | - |
The average 5 years interest of tipifarnib was 8.22 per week. The last year interest of tipifarnib compared to the last 5 years has changed by -0.61%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 31.14%.
There is not enough data for farnesyl transferase inhibitor to provide analysis
There is not enough data for farnesyl transferase inhibitor to provide correlation calculation
There is not enough data for farnesyl transferase inhibitor to provide analysis
Google Trends for solid tumors
Q4 +25.8% YoY, +4.5% QoQ | Q1 -7.5% YoY, +9.0% QoQ | Correlation: nan
After 39 days of this quarter the interest is at 267.0. Based on that we can calculate that during remaining 52 days it will total up to 623.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 306 | 412 34.6% QoQ | 434 5.3% QoQ | 380 -12.4% QoQ |
| 2020 | 401 31.0% YoY 5.5% QoQ | 417 1.2% YoY 4.0% QoQ | 435 0.2% YoY 4.3% QoQ | 471 23.9% YoY 8.3% QoQ |
| 2021 | 435 8.5% YoY -7.6% QoQ | 384 -7.9% YoY -11.7% QoQ | 402 -7.6% YoY 4.7% QoQ | 440 -6.6% YoY 9.5% QoQ |
| 2022 | 643 47.8% YoY 46.1% QoQ | 619 61.2% YoY -3.7% QoQ | 517 28.6% YoY -16.5% QoQ | 494 12.3% YoY -4.4% QoQ |
| 2023 | 724 12.6% YoY 46.6% QoQ | 643 3.9% YoY -11.2% QoQ | 597 15.5% YoY -7.2% QoQ | 585 18.4% YoY -2.0% QoQ |
| 2024 | 267 -63.1% YoY -54.4% QoQ | - | - | - |
The average 5 years interest of solid tumors was 38.34 per week. The last year interest of solid tumors compared to the last 5 years has changed by 25.04%. The interest for solid tumors is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 46.02%.
There is not enough data for hematologic indications to provide analysis
There is not enough data for hematologic indications to provide correlation calculation
There is not enough data for hematologic indications to provide analysis
There is not enough data for Kura Oncology clinical collaboration to provide analysis
There is not enough data for Kura Oncology clinical collaboration to provide correlation calculation
There is not enough data for Kura Oncology clinical collaboration to provide analysis
After 34 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 58 days it will total up to 0.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 269 |
| 2019 | 558 107.4% QoQ | 569 2.0% QoQ | 550 -3.3% QoQ | 478 77.7% YoY -13.1% QoQ |
| 2020 | 564 1.1% YoY 18.0% QoQ | 544 -4.4% YoY -3.5% QoQ | 457 -16.9% YoY -16.0% QoQ | 362 -24.3% YoY -20.8% QoQ |
| 2021 | 399 -29.3% YoY 10.2% QoQ | 370 -32.0% YoY -7.3% QoQ | 364 -20.4% YoY -1.6% QoQ | 380 5.0% YoY 4.4% QoQ |
| 2022 | 359 -10.0% YoY -5.5% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ |
| 2023 | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ |
The average 5 years interest of Novartis was 23.93 per week. The last year interest of Novartis compared to the last 5 years has changed by -100.0%. The interest for Novartis is significantly decreasing. The last year interest is quite lower compared to 5 years ago. It has decreased by -100.0%.
There is not enough data for tipifarnib and alpelisib to provide analysis
There is not enough data for tipifarnib and alpelisib to provide correlation calculation
There is not enough data for tipifarnib and alpelisib to provide analysis
After 39 days of this quarter the interest is at 152.0. Based on that we can calculate that during remaining 52 days it will total up to 355.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 424 | 282 -33.5% QoQ | 444 57.4% QoQ | 308 -30.6% QoQ |
| 2020 | 403 -5.0% YoY 30.8% QoQ | 366 29.8% YoY -9.2% QoQ | 469 5.6% YoY 28.1% QoQ | 454 47.4% YoY -3.2% QoQ |
| 2021 | 404 0.2% YoY -11.0% QoQ | 465 27.0% YoY 15.1% QoQ | 377 -19.6% YoY -18.9% QoQ | 401 -11.7% YoY 6.4% QoQ |
| 2022 | 539 33.4% YoY 34.4% QoQ | 458 -1.5% YoY -15.0% QoQ | 443 17.5% YoY -3.3% QoQ | 420 4.7% YoY -5.2% QoQ |
| 2023 | 334 -38.0% YoY -20.5% QoQ | 370 -19.2% YoY 10.8% QoQ | 528 19.2% YoY 42.7% QoQ | 474 12.9% YoY -10.2% QoQ |
| 2024 | 152 -54.5% YoY -67.9% QoQ | - | - | - |
The average 5 years interest of head and neck squamous cell carcinoma was 32.62 per week. The last year interest of head and neck squamous cell carcinoma compared to the last 5 years has changed by 0.0%. The interest for head and neck squamous cell carcinoma is seasonal. The last year interest is comparable to 5 years ago. It has changed only by 4.05%.
There is not enough data for HRAS overexpression to provide analysis
There is not enough data for HRAS overexpression to provide correlation calculation
There is not enough data for HRAS overexpression to provide analysis
After 39 days of this quarter the interest is at 80.0. Based on that we can calculate that during remaining 52 days it will total up to 187.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 23 | 139 504.3% QoQ | 199 43.2% QoQ | 299 50.3% QoQ |
| 2020 | 266 1056.5% YoY -11.0% QoQ | 230 65.5% YoY -13.5% QoQ | 117 -41.2% YoY -49.1% QoQ | 102 -65.9% YoY -12.8% QoQ |
| 2021 | 234 -12.0% YoY 129.4% QoQ | 226 -1.7% YoY -3.4% QoQ | 108 -7.7% YoY -52.2% QoQ | 282 176.5% YoY 161.1% QoQ |
| 2022 | 228 -2.6% YoY -19.1% QoQ | 221 -2.2% YoY -3.1% QoQ | 229 112.0% YoY 3.6% QoQ | 129 -54.3% YoY -43.7% QoQ |
| 2023 | 181 -20.6% YoY 40.3% QoQ | 196 -11.3% YoY 8.3% QoQ | 176 -23.1% YoY -10.2% QoQ | 305 136.4% YoY 73.3% QoQ |
| 2024 | 80 -55.8% YoY -73.8% QoQ | - | - | - |
The average 5 years interest of PIK3CA mutation was 15.21 per week. The last year interest of PIK3CA mutation compared to the last 5 years has changed by 7.63%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 7.34%.
There is not enough data for Kura Oncology headquarters to provide analysis
There is not enough data for Kura Oncology headquarters to provide correlation calculation
There is not enough data for Kura Oncology headquarters to provide analysis